Powered by
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company developing novel treatments for endocrine diseases with significant unmet needs, reported a loss of $12 million or 65 cents per …
ANN ARBOR—Millendo Therapeutics Inc., a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases, announced today that it is discontinuing the development of livoletide as a potential treatment …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a pharmaceutical startup focused on developing novel treatments for orphan endocrine diseases, provided a corporate update and reported financial results for the year ended …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced that Christophe Arbet-Engels has joined the company as Chief Medical …
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), a biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, announced that Geoff Nichol has been appointed …
ANN ARBOR—Millendo Therapeutics Inc., (Nasdaq: MLND), a clinical-stage pharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, provided a corporate update and reported …
ANN ARBOR –Millendo Therapeutics Inc. (Nasdaq: MLND), the Ann Arbor pharmaceutical company developing treatments for endocrine diseases, announced the grant of inducement stock options to three new employees of the …